Research graph
References from PI3K Inhibition Augments the Therapeutic Efficacy of a 3a-aza-Cyclopenta[α]indene Derivative in Lung Cancer Cells. Local targets link to admitted publications; unresolved targets remain external evidence.
Timeline: chemotherapy and the war on cancer
10.1038/nrc1529 · 2005 · External reference
Management of small cell lung cancer: recent developments for optimal care
10.2165/11597640-000000000-00000 · 2012 · External reference
Bendamustine: a review of its use in the management of chronic lymphocytic leukaemia, rituximab-refractory indolent non-Hodgkin's lymphoma and multiple myeloma
10.2165/11209510-000000000-00000 · 2012 · External reference
DNA repair pathways as targets for cancer therapy
10.1038/nrc2342 · 2008 · External reference
DNA interstrand cross-linking agents and their chemotherapeutic potential
10.2174/092986712803414295 · 2012 · External reference
The DNA damage response and cancer therapy
10.1038/nature10760 · 2012 · External reference
The MRE11 complex: starting from the ends
10.1038/nrm3047 · 2011 · External reference
Harnessing synthetic lethal interactions in anticancer drug discovery
10.1038/nrd3374 · 2011 · External reference
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
10.1038/nrg1879 · 2006 · External reference
PKB/Akt promotes DSB repair in cancer cells through upregulating Mre11 expression following ionizing radiation
10.1038/onc.2010.467 · 2011 · External reference
Inhibition of phosphatidylinositol-3-OH kinase/Akt signaling impairs DNA repair in glioblastoma cells following ionizing radiation
10.1074/jbc.m703042200 · 2007 · External reference
Down-regulation of Rad51 expression overcomes drug resistance to gemcitabine in human non-small-cell lung cancer cells
10.1124/jpet.110.173146 · 2010 · External reference
Targeting of AKT1 enhances radiation toxicity of human tumor cells by inhibiting DNA-PKcs-dependent DNA double-strand break repair
10.1158/1535-7163.mct-07-2200 · 2008 · External reference
DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation
10.1038/nature01368 · 2003 · External reference
Distinct functional domains of Nbs1 modulate the timing and magnitude of ATM activation after low doses of ionizing radiation
10.1038/sj.onc.1207447 · 2004 · External reference
Targeting the phosphoinositide 3-kinase pathway in cancer
10.1038/nrd2926 · 2009 · External reference
Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises
10.1016/j.coph.2008.08.004 · 2008 · External reference
Class I PI3 kinase inhibition by the pyridinylfuranopyrimidine inhibitor PI-103 enhances tumor radiosensitivity
10.1158/0008-5472.can-08-0757 · 2008 · External reference
Drug discovery approaches targeting the PI3K/Akt pathway in cancer
10.1038/onc.2008.246 · 2008 · External reference
Biochemical characterization of the ataxia-telangiectasia mutated (ATM) protein from human cells
10.1016/j.dnarep.2004.03.041 · 2004 · External reference
In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002)
2000 · External reference
Phosphatidylinositol 3-kinase inhibitor(LY294002) induces apoptosis of human nasopharyngeal carcinoma in vitro and in vivo
10.1186/1756-9966-29-34 · 2010 · External reference
Inhibition of the phosphatidylinositol 3′-kinase-AKT pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivo
2002 · External reference
The in vitro and in vivo effects of 2-(4-morpholinyl)-8-phenyl-chromone (LY294002), a specific inhibitor of phosphatidylinositol 3′-kinase, in human colon cancer cells
2002 · External reference
Disulfiram treatment facilitates phosphoinositide 3-kinase inhibition in human breast cancer cells in vitro and in vivo
10.1158/0008-5472.can-09-3752 · 2010 · External reference
Inhibition of phosphatidylinositol 3′-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models
2002 · External reference
Phosphatidylinositol 3-kinase inhibition by LY294002 radiosensitizes human cervical cancer cell lines
10.1158/1078-0432.ccr-05-1084 · 2006 · External reference
Potent antitumor bifunctional DNA alkylating agents, synthesis and biological activities of 3a-aza-cyclopenta[a]indenes
10.1016/j.bmc.2009.06.018 · 2009 · External reference
IFN-induced protein with tetratricopeptide repeats 2 inhibits migration activity and increases survival of oral squamous cell carcinoma
10.1158/1541-7786.mcr-08-0141 · 2008 · External reference
The novel DNA alkylating agent BO-1090 suppresses the growth of human oral cavity cancer in xenografted and orthotopic mouse models
10.1002/ijc.26142 · 2012 · External reference
Combination of bifunctional alkylating agent and arsenic trioxide synergistically suppresses the growth of drug-resistant tumor cells
10.1593/neo.10110 · 2010 · External reference
DNA interstrand crosslink repair in mammalian cells: step by step
10.3109/10409230903501819 · 2010 · External reference
PI3K/Akt signalling pathway specific inhibitors: a novel strategy to sensitize cancer cells to anti-cancer drugs
10.2174/138161210791033950 · 2010 · External reference
PI3 kinase inhibitors in the clinic: an update
2012 · External reference
Highlights in lung cancer
10.1183/09031936.01.00238801 · 2001 · External reference
Recent advances in non-small cell lung cancer biology and clinical management
2012 · External reference
Strategies for improving outcomes in NSCLC: a look to the future
10.1016/j.lungcan.2013.08.025 · 2013 · External reference
Treatment of non–small-cell lung cancer with erlotinib or gefitinib
10.1056/nejmct0807960 · 2011 · External reference
Gefitinib or chemotherapy for non–small-cell lung cancer with mutated EGFR
10.1056/nejmoa0909530 · 2010 · External reference
Shortcomings of current therapies for non-small-cell lung cancer: unmet medical needs
10.1038/onc.2009.196 · 2009 · External reference
Slug confers resistance to the epidermal growth factor receptor tyrosine kinase inhibitor
10.1164/rccm.201009-1440oc · 2011 · External reference
Trifluoperazine, an antipsychotic agent, inhibits cancer stem cell growth and overcomes drug resistance of lung cancer
10.1164/rccm.201207-1180oc · 2012 · External reference
Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies
10.1124/pr.58.3.10 · 2006 · External reference
High throughput evaluation of gamma-H2AX
10.1186/1748-717x-4-31 · 2009 · External reference
ATR: an essential regulator of genome integrity
10.1038/nrm2450 · 2008 · External reference
A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002)
10.1016/s0021-9258(17)37680-9 · 1994 · External reference
γH2AX and cancer
10.1038/nrc2523 · 2008 · External reference
DNA double-strand break repair: from mechanistic understanding to cancer treatment
10.1016/j.dnarep.2007.02.006 · 2007 · External reference
Aberrations of the MRE11-RAD50-NBS1 DNA damage sensor complex in human breast cancer: MRE11 as a candidate familial cancer-predisposing gene
10.1016/j.molonc.2008.09.007 · 2008 · External reference
The Fanconi anemia pathway and ubiquitin
10.1186/1471-2091-8-s1-s10 · 2007 · External reference
To the rescue: the Fanconi anemia genome stability pathway salvages replication forks
10.1016/j.ccr.2012.06.006 · 2012 · External reference
Phosphatidylinositol 3-kinase mediates activation of ATM by high NaCl and by ionizing radiation: role in osmoprotective transcriptional regulation
10.1073/pnas.0602911103 · 2006 · External reference
LY294002 may overcome 5-FU resistance via down-regulation of activated p-AKT in Epstein-Barr virus-positive gastric cancer cells
10.1186/1471-2407-10-425 · 2010 · External reference
ATM-related Tel1 associates with double-strand breaks through an Xrs2-dependent mechanism
10.1101/gad.1099003 · 2003 · External reference
Direct activation of the ATM protein kinase by the Mre11/Rad50/Nbs1 complex
10.1126/science.1091496 · 2004 · External reference
DNA double-strand break repair signalling: the case of RAD51 post-translational regulation
10.1016/s0898-6568(02)00052-9 · 2002 · External reference
Nuclear foci of mammalian Rad51 recombination protein in somatic cells after DNA damage and its localization in synaptonemal complexes
10.1073/pnas.92.6.2298 · 1995 · External reference
Double functions for the Mre11 complex during DNA double-strand break repair and replication
10.1016/j.biocel.2008.12.013 · 2009 · External reference
The Mre11-Rad50-Xrs2 protein complex facilitates homologous recombination-based double-strand break repair in Saccharomyces cerevisiae
10.1128/mcb.19.11.7681 · 1999 · External reference
Budding yeast Sae2 is an in vivo target of the Mec1 and Tel1 checkpoint kinases during meiosis
10.4161/cc.5.14.2916 · 2006 · External reference
Drug combination studies and their synergy quantification using the Chou-Talalay method
10.1158/0008-5472.can-09-1947 · 2010 · External reference
High-dose chemotherapy regimens for solid tumors
10.1016/0305-7372(95)90023-3 · 1995 · External reference
Mitomycin C: mechanism of action, usefulness and limitations
10.1097/00001813-199010000-00002 · 1990 · External reference
Global cancer statistics
10.3322/caac.20107 · 2011 · External reference
Lung cancer
10.1002/1097-0142(19950101)75:1+<191::aid-cncr2820751307>3.0.co;2-y · 1995 · External reference
Clinical and cost effectiveness of paclitaxel, docetaxel, gemcitabine, and vinorelbine in non-small cell lung cancer: a systematic review
10.1136/thorax.57.1.20 · 2002 · External reference
Erlotinib in previously treated non–small-cell lung cancer
10.1056/nejmoa050753 · 2005 · External reference
Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non–small-cell lung cancers dependent on the epidermal growth factor receptor pathway
10.3816/clc.2009.n.039 · 2009 · External reference
Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer
10.1038/nrc2947 · 2010 · External reference
